Institution · Lou Ruvo Brain Institute
Most cited papers from Lou Ruvo Brain Institute
What are the most cited papers from Lou Ruvo Brain Institute?
The most cited paper from Lou Ruvo Brain Institute is "Alzheimer's disease" (Philip Scheltens, Bart De Strooper, Miia Kivipelto et al., 2021), with 5,240 citations. Next come "Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria" (3,373) and "Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing" (3,277).
Showing 50 of 60 papers. Every paper with more than 209 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Alzheimer's disease Philip Scheltens, Bart De Strooper, Miia Kivipelto et al. · The Lancet | 2 Mar 2021 | 5,240 |
| 2 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Bruno Dubois et al. · The Lancet Neurology | 18 May 2014 | 3,373 |
| 3 | Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing Brian W. Kunkle et al. · Nature Genetics | 28 Feb 2019 | 3,277 |
| 4 | New insights into the genetic etiology of Alzheimer’s disease and related dementias Céline Bellenguez et al. · Nature Genetics | Apr 2022 | 2,608 |
| 5 | Analysis of shared heritability in common disorders of the brain Verneri Anttila et al. · Science | 21 Jun 2018 | 2,056 |
| 6 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria Bruno Dubois et al. · Alzheimer s & Dementia | Mar 2016 | 1,953 |
| 7 | Alzheimer's disease Colin Louis Masters, Randall John Bateman, Kaj Blennow et al. · Nature Reviews Disease Primers | 15 Oct 2015 | 1,818 |
| 8 | Alzheimer’s disease drug-development pipeline: few candidates, frequent failures Jeffrey L. Cummings, Travis Morstorf, Kate Zhong · Alzheimer s Research & Therapy | 3 Jul 2014 | 1,787 |
| 9 | Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis Yasser Iturria‐Medina et al. · Nature Communications | 21 Jun 2016 | 1,244 |
| 10 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease Rebecca C. Sims et al. · Nature Genetics | 17 Jul 2017 | 1,122 |
| 11 | Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group Bruno Dubois, Nicolas Villain, Giovanni Battista Frisoni et al. · The Lancet Neurology | 29 Apr 2021 | 1,065 |
| 12 | Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet | 31 Oct 2013 | 955 |
| 13 | Alzheimer's disease drug development pipeline: 2019 Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions | 2019 | 780 |
| 14 | Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021 Anton P. Porsteinsson, Richard Isaacson, S. Knox et al. · The Journal of Prevention of Alzheimer s Disease | 4 Jun 2021 | 738 |
| 15 | Alzheimer's disease drug development pipeline: 2018 Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions | 2018 | 730 |
| 16 | Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease Michael F. Egan, James T. Kost, Pierre N. Tariot et al. · New England Journal of Medicine | 2 May 2018 | 701 |
| 17 | TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models Taylor R. Jay, Crystal M. Miller, Paul J. Cheng et al. · The Journal of Experimental Medicine | 2 Mar 2015 | 699 |
| 18 | Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference Alexandra L. Young et al. · Nature Communications | 9 Oct 2018 | 613 |
| 19 | Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis David John Irwin et al. · The Lancet Neurology | 6 Dec 2016 | 608 |
| 20 | Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options Jeffrey L. Cummings, Gary Tong, Clive G. Ballard · Journal of Alzheimer s Disease | 22 Jan 2019 | 594 |
| 21 | On the path to 2025: understanding the Alzheimer’s disease continuum Paul S. S. Aisen, Jeffrey L. Cummings, Clifford R. Jack et al. · Alzheimer s Research & Therapy | 9 Aug 2017 | 575 |
| 22 | Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease Jacob W. Vogel et al. · Nature Communications | 26 May 2020 | 568 |
| 23 | The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations Zahinoor Ismail, Luis Agüera-Ortíz, Henry Brodaty et al. · Journal of Alzheimer s Disease | 6 Jan 2017 | 566 |
| 24 | Alzheimer's disease drug development pipeline: 2020 Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions | 2020 | 565 |
| 25 | Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease Michael F. Egan, James T. Kost, Tiffini Voss et al. · New England Journal of Medicine | 10 Apr 2019 | 561 |
| 26 | Alzheimer's disease drug development pipeline: 2017 Jeffrey L. Cummings, Yadi Zhou, Yuxin Yang et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions | 24 May 2017 | 552 |
| 27 | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study John Matthew Ringman, Sally Ann Frautschy, Edmond Teng et al. · Alzheimer s Research & Therapy | 29 Oct 2012 | 545 |
| 28 | Current state of Alzheimer’s fluid biomarkers José Luís Molinuevo, Scott Ayton, Richard Batrla et al. · Acta Neuropathologica | 28 Nov 2018 | 533 |
| 29 | The probabilistic model of Alzheimer disease: the amyloid hypothesis revised Giovanni Battista Frisoni, Daniele Altomare, Dietmar Rudolf Thal et al. · Nature reviews. Neuroscience | 23 Nov 2021 | 515 |
| 30 | Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study Eric M. Reiman et al. · Nature Communications | 3 Feb 2020 | 513 |
| 31 | Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture Ruth Chia et al. · Nature Genetics | 15 Feb 2021 | 494 |
| 32 | Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease Tae‐In Kam et al. · Science | Nov 2018 | 478 |
| 33 | Drug development in Alzheimer’s disease: the path to 2025 Jeffrey L. Cummings, Paul S. S. Aisen, Bruno Dubois et al. · Alzheimer s Research & Therapy | 13 Sep 2016 | 468 |
| 34 | Predicting Alzheimer’s disease progression using multi-modal deep learning approach Garam Lee et al. · Scientific Reports | 13 Feb 2019 | 415 |
| 35 | Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images Donghuan Lu et al. · Scientific Reports | 3 Apr 2018 | 384 |
| 36 | A Systematic Review of Dementia-related Stigma Research: Can We Move the Stigma Dial? Lynn Katherine Herrmann, Elisabeth Welter, James B. Leverenz et al. · American Journal of Geriatric Psychiatry | 12 Sep 2017 | 380 |
| 37 | The neurobiological basis of cognitive impairment in Parkinson's disease Glenda Margaret Halliday, James B. Leverenz, Jay S. Schneider et al. · Movement Disorders | 15 Apr 2014 | 373 |
| 38 | Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease Jeffrey L. Cummings, Amanda M. Leisgang Osse, Davis Cammann et al. · BioDrugs | 13 Nov 2023 | 372 |
| 39 | Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology Taylor W. Schmitz et al. · Nature Communications | 4 Nov 2016 | 365 |
| 40 | Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition Jeffrey L. Cummings, Jacobo E Mintzer, Henry Brodaty et al. · International Psychogeriatrics | 14 Oct 2014 | 363 |
| 41 | Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval Martin Tolar, Susan R. Abushakra, John A. Hey et al. · Alzheimer s Research & Therapy | 12 Aug 2020 | 361 |
| 42 | Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease Nicolai Franzmeier et al. · Nature Communications | 17 Jan 2020 | 360 |
| 43 | Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event Darin T. Okuda et al. · PLoS ONE | 5 Mar 2014 | 338 |
| 44 | Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis Jerome Liss et al. · Journal of Internal Medicine | 18 Jan 2021 | 332 |
| 45 | Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes Jeffrey L. Cummings · Clinical and Translational Science | 2 Aug 2017 | 311 |
| 46 | Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease Daniel A. Weintraub, Tanya Simuni, Chelsea Caspell‐Garcia et al. · Movement Disorders | 4 Mar 2015 | 310 |
| 47 | The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis Martin Tolar, Susan R. Abushakra, Marwan Noel Sabbagh · Alzheimer s & Dementia | 6 Nov 2019 | 286 |
| 48 | Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression Amit N. Anand et al. · New England Journal of Medicine | 24 May 2023 | 275 |
| 49 | The Neuropsychiatric Inventory: Development and Applications Jeffrey L. Cummings · Journal of Geriatric Psychiatry and Neurology | 4 Feb 2020 | 267 |
| 50 | Ageing and multiple sclerosis Jennifer S. Graves, Kristen M. Krysko, Le Hanh Hua et al. · The Lancet Neurology | 7 Oct 2022 | 261 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.